-+ 0.00%
-+ 0.00%
-+ 0.00%

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Barchart·12/17/2025 05:30:00
Listen to the news

-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA --

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.